Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti | Zendy

Samuel Pierre | Zendy; Iryna Bocharova | Zendy; Catherine Nguyen | Zendy; Fabienne Homeus | Zendy; Gaetane Julmiste | Zendy; Youry Macius | Zendy; Vanessa Rouzier | Zendy; Patrice Sévère | Zendy; Marie Deschamps | Zendy; Colette Guiteau Moïse | Zendy; Clovy Bellot | Zendy; Johnny Wu | Zendy; Vanessa Rivera | Zendy; Rochelle Sun | Zendy; Jean W. Pape | Zendy; Bernard Liautaud | Zendy; Serena P. Koenig | Zendy

Open Access

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Author(s) -

Samuel Pierre,

Iryna Bocharova,

Catherine Nguyen,

Fabienne Homeus,

Gaetane Julmiste,

Youry Macius,

Vanessa Rouzier,

Patrice Sévère,

Marie Deschamps,

Colette Guiteau Moïse,

Clovy Bellot,

Johnny Wu,

Vanessa Rivera,

Rochelle Sun,

Jean W. Pape,

Bernard Liautaud,

Serena P. Koenig

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab559

Subject(s) - tenofovir , zidovudine , medicine , antiretroviral therapy , second line therapy , human immunodeficiency virus (hiv) , second line , virology , family medicine , viral load , first line , viral disease , chemotherapy

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research